Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group

Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Hilar Cholangiocarcinoma

(2020) Alexandra Zaborowski et al.   TRANSPLANTATION

mTOR Inhibitors in Advanced Biliary Tract Cancers

(2019) Chao-En Wu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma

(2019) Sam E. Grigg et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Reassessing the role of liver transplantation for patients with metastatic colorectal cancer to the liver

(2019) Pranit Chotai et al.   Current Opinion in Organ Transplantation

Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases

(2019) Svein Dueland et al.   ANNALS OF SURGERY

Delayed kidney transplantation in combined liver‐kidney transplantation for polycystic liver and kidney disease

(2019) Andrea Lauterio et al.   TRANSPLANT INTERNATIONAL

Current status of liver transplantation for cholangiocarcinoma

(2018) Nicolás Goldaracena et al.   LIVER TRANSPLANTATION

International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

(2018) Michael Charlton et al.   TRANSPLANTATION

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

(2018) B. Rousseau et al.   INTERNATIONAL JOURNAL OF CANCER

Dual Function of IRF1/IRF4 on Dendritic Cells During Mouse Liver Transplantation

(2018) Guangxiang Gu et al.   TRANSPLANTATION

Liver Transplantation for Neuroendocrine Tumors: What Have We Learned?

(2018) Chetana Lim et al.   SEMINARS IN LIVER DISEASE

A multicenter study to define sarcopenia in patients with end-stage liver disease

(2017) Elizabeth J. Carey et al.   LIVER TRANSPLANTATION

Use of Everolimus in Liver Transplantation

(2017) Paolo De Simone et al.   TRANSPLANTATION

The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors

(2016) V. Mazzaferro et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts

(2016) Nils Heits et al.   BMC CANCER

Combined liver-kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset

(2016) Cristin Coquillard et al.   LIVER INTERNATIONAL

Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma

(2016) Elizabeth L. Yanik et al.   LIVER TRANSPLANTATION

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

(2016) Edward K. Geissler et al.   TRANSPLANTATION

A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a “Blended Principle Model”

(2015) U. Cillo et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus

(2015) Lutz Fischer et al.   TRANSPLANTATION

Neoplastic disease after liver transplantation: Focus onde novoneoplasms

(2015) Patrizia Burra   WORLD JOURNAL OF GASTROENTEROLOGY

Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

(2014) M. Sterneck et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation

(2014) G. Sapisochin et al.   ANNALS OF SURGERY

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review

(2014) Evangelos Cholongitas et al.   TRANSPLANT INTERNATIONAL

Efficacy and Safety of Combination Therapy With Everolimus and Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation

(2014) P. De Simone et al.   TRANSPLANTATION PROCEEDINGS

Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

(2013) F. Saliba et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer

(2013) Morten Hagness et al.   ANNALS OF SURGERY

Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index

(2013) Lisa Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of polycystic liver disease

(2013) Tom J. G. Gevers et al.   Nature Reviews Gastroenterology & Hepatology

Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial

(2012) M. F. Abdelmalek et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation-PROTECT

(2012) L. Fischer et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Everolimus With Reduced Tacrolimus Improves Renal Function inDe NovoLiver Transplant Recipients: A Randomized Controlled Trial

(2012) P. De Simone et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009

(2012) Pierluca Piselli et al.   EUROPEAN JOURNAL OF CANCER

Liver Transplantation for the Treatment of Liver Metastases From Neuroendocrine Tumors

(2011) Roberto Gedaly   ARCHIVES OF SURGERY

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

(2011) Carlos Gomez-Martin et al.   LIVER TRANSPLANTATION

Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

(2011) Faouzi Saliba et al.   LIVER TRANSPLANTATION

Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function

(2010) M. Masetti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Medical and surgical treatment options for polycystic liver disease1

(2010) Joost P.H. Drenth et al.   HEPATOLOGY

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle

(2010) Sherrie Bhoori et al.   JOURNAL OF HEPATOLOGY

Sirolimus in Liver Transplant Recipients: A Large Single-Center Experience

(2010) M. Vivarelli et al.   TRANSPLANTATION PROCEEDINGS

Management of renal dysfunction in the liver transplant recipient

(2009) Phuong-Thu T Pham et al.   Current Opinion in Organ Transplantation

mTOR inhibitors for hepatocellular cancer: a forward-moving target

(2009) Gerhard Treiber   Expert Review of Anticancer Therapy

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma

(2009) Christian Toso et al.   HEPATOLOGY

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

(2009) Javier F. Castroagudín et al.   LIVER TRANSPLANTATION

Renal outcomes after liver transplantation in the model for end-stage liver disease era

(2009) Pratima Sharma et al.   LIVER TRANSPLANTATION

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial

(2009) Paolo De Simone et al.   LIVER TRANSPLANTATION

The Impact of Everolimus on Renal Function in Maintenance Liver Transplantation

(2009) P. De Simone et al.   TRANSPLANTATION PROCEEDINGS

Indications and Management of Everolimus After Liver Transplantation

(2009) I. Bilbao et al.   TRANSPLANTATION PROCEEDINGS

Overview of immunosuppression in liver transplantation

(2009) Anjana A Pillai et al.   WORLD JOURNAL OF GASTROENTEROLOGY